We have been reasonably sanguine about the markets because valuations don't look overly expensive. In Europe, earnings have clearly had the global recovery element to them.
I think it's pretty unlikely.
Clearly drug companies that have got strong products have done a great job.
Copyright © 2024 Electric Goat Media. All Rights Reserved.